此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项为期 52 周的研究,旨在了解 Ritlecitinib 对非节段性白癜风参与者的安全性和效果 (Tranquillo LTE)

2026年9月24日 更新者:Pfizer

一项 3 期随机停药和剂量递增滴定、多中心延伸研究,调查利特西替尼在患有非节段性白癜风的成人和青少年参与者中的安全性、有效性和耐受性

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).

Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin.

Non-segmental vitiligo is an autoimmune disorder and is the focus of this study. The study will show:

  • if the repigmentation (the recovery of pigmentation) achieved in study B7981040 (also called the "parent study") will stay the same or will further increase if you keep receiving the same study medicine (ritlecitinib 50 milligrams or placebo)
  • Or if more repigmentation can be achieved if you start receiving ritlecitinib 100 milligrams in this study
  • Or how long the repigmentation achieved during the parent study lasts if you start receiving placebo in this study.

This study is seeking for participants who:

  • have non-segmental vitiligo (either active or stable) and
  • received ritlecitinib or placebo for 52 weeks in the parent study. A placebo looks exactly like the study capsule but does not contain any medicine in it.

All participants in this study will receive the study medicine or placebo. The study medicine (ritlecitinib 50 milligrams or 100 milligrams) or placebo are capsules that are taken by mouth at home every day. On study visit days, you must take the medication at the study site, and not at home.

Participants may receive the study medicine or placebo for up to 52 weeks.

The study will look at the experiences of people receiving the study medicine. This will help see if ritlecitinib is better for treating vitiligo.

Participants will be involved in this study for a maximum of 60 weeks. During this time, they will have 9 study visits during the study.

Ritlecitinib 50 mg is an approved drug for the treatment of severe Alopecia Areata (a disease with similar abnormal changes in the body functions like vitiligo) in the US, EU and Japan. China, Great Britain and other market applications are pending.

研究概览

研究类型

介入性

注册 (实际的)

394

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Guangdong
      • Guangzhou、Guangdong、中国、510091
        • Dermatology Hospital of Southern Medical University
    • Hubei
      • Wuhan、Hubei、中国、430022
        • The First Hospital of Wuhan
    • Liaoning
      • Shenyang、Liaoning、中国、110001
        • The First Hospital of China Medical University/Dermatology and STD Department
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200040
        • Huashan Hospital Fudan University
    • Yunnan
      • Kunming、Yunnan、中国、650032
        • First Affiliated Hospital of Kunming Medical University
      • Stara Zagora、保加利亚、6003
        • UMHAT "Prof. Dr. Stoyan Kirkovich"AD
    • Kyustendil
      • Dupnitsa、Kyustendil、保加利亚、2600
        • Medical Centre "Asklepiy"
    • Sofia (stolitsa)
      • Sofia、Sofia (stolitsa)、保加利亚、1431
        • Diagnostic Consultative Center Aleksandrovska
      • Québec、加拿大、G1V 4X7
        • Centre de Recherche Dermatologique du Quebec metropolitain
      • Québec、加拿大、G1W 4R4
        • Centre de Recherche Saint-Louis inc.
    • Alberta
      • Calgary、Alberta、加拿大、T2J 7E1
        • Dermatology Research Institute
      • Red Deer、Alberta、加拿大、T4P 1K4
        • CaRe Clinic
    • Ontario
      • Markham、Ontario、加拿大、L3P 1X3
        • Lynderm Research Inc.
      • Mississauga、Ontario、加拿大、L4Y 4C5
        • DermEdge Research
      • Toronto、Ontario、加拿大、M2N3A6
        • North York Research Inc
      • Istanbul、土耳其(türkiye)、34098
        • Istanbul Universitesi Cerrahpasa
      • Kayseri、土耳其(türkiye)
        • Erciyes Universitesi Tıp Fakultesi Hastaneleri
      • Manisa、土耳其(türkiye)、45030
        • Celal Bayar University Hafsa Sultan Hospital
    • İ̇stanbul
      • Istanbul、İ̇stanbul、土耳其(türkiye)、34899
        • Marmara Universitesi Pendik Egitim Arastirma Hastanesi
      • Veracruz、墨西哥、91900
        • Arké SMO S.A de C.V
      • Veracruz、墨西哥、91900
        • Sociedad de Metabolismo y Corazon S.C.
    • Mexico City
      • Mexico City、Mexico City、墨西哥、06720
        • Hospital Infantil de Mexico Federico Gomez
    • Nuevo León
      • Monterrey、Nuevo León、墨西哥、64460
        • Centro de Dermatologia de Monterrey
    • Baden-Wurttemberg
      • Stuttgart、Baden-Wurttemberg、德国、70178
        • Praxis Leitz und Kollegen
    • Lower Saxony
      • Bad Bentheim、Lower Saxony、德国、48455
        • Fachklinik Bad Bentheim
    • North Rhine-Westphalia
      • Münster、North Rhine-Westphalia、德国、48149
        • Universitätsklinikum Münster
    • Aichi-ken
      • Nagoya、Aichi-ken、日本、467-8602
        • Nagoya City University Hospital
    • Miyagi
      • Sendai、Miyagi、日本、980-8574
        • Tohoku University Hospital
    • Osaka
      • Sakai、Osaka、日本、593-8324
        • Dermatology and Ophthalmology Kume Clinic
    • Tokyo
      • Bunkyo-ku、Tokyo、日本、113-8603
        • Nippon Medical School Hospital
      • Shinjuku-ku、Tokyo、日本、160-0023
        • Tokyo Medical University Hospital
    • Yamanashi
      • Kofu、Yamanashi、日本、400-8506
        • Yamanashi Prefectural Central Hospital
    • Kuyavian-Pomeranian Voivodeship
      • Osielsko、Kuyavian-Pomeranian Voivodeship、波兰、86-031
        • DermoDent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski s.c.
    • Masovian Voivodeship
      • Warsaw、Masovian Voivodeship、波兰、02-962
        • Royalderm Agnieszka Nawrocka
    • West Pomeranian Voivodeship
      • Szczecin、West Pomeranian Voivodeship、波兰、71-500
        • Twoja Przychodnia SCM
    • Łódź Voivodeship
      • Lodz、Łódź Voivodeship、波兰、90-436
        • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
    • Świętokrzyskie Voivodeship
      • Ostrowiec Świętokrzyski、Świętokrzyskie Voivodeship、波兰、27-400
        • Dermedic Jacek Zdybski
    • New South Wales
      • Darlinghurst、New South Wales、澳大利亚、2010
        • The Skin Hospital
    • South Australia
      • Campbelltown、South Australia、澳大利亚、5074
        • North Eastern Health Specialists
    • Victoria
      • Carlton、Victoria、澳大利亚、3053
        • Skin Health Institute Inc.
      • East Melbourne、Victoria、澳大利亚、3002
        • Dr Rodney Sinclair Pty Ltd
      • Melbourne、Victoria、澳大利亚、3004
        • The Alfred Hospital
    • California
      • Encinitas、California、美国、92024
        • California Dermatology & Clinical Research Institute
      • Huntington Beach、California、美国、92647
        • Marvel Clinical Research
      • Los Angeles、California、美国、90056
        • Wallace Medical Group, Inc
    • Florida
      • Boynton Beach、Florida、美国、33436
        • Encore Medical Research of Boynton Beach
      • Hollywood、Florida、美国、33021
        • Skin Care Research
      • Tampa、Florida、美国、33613
        • ForCare Clinical Research
    • Indiana
      • Indianapolis、Indiana、美国、46250
        • Dawes Fretzin Clinical Research Group, LLC
    • Louisiana
      • Baton Rouge、Louisiana、美国、70809
        • DelRicht Research
    • Maryland
      • Rockville、Maryland、美国、20850
        • Lawrence J. Green, MD LLC
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • University of Michigan
    • New Mexico
      • Albuquerque、New Mexico、美国、87102
        • University of New Mexico Health Sciences Center
    • New York
      • Brooklyn、New York、美国、11203
        • SUNY Downstate Health Sciences University
    • North Carolina
      • Chapel Hill、North Carolina、美国、27516
        • University of North Carolina Medical Center
      • Chapel Hill、North Carolina、美国、27599
        • Clinical & Translational Research Center (CTRC)
      • Wilmington、North Carolina、美国、28411
        • Accellacare - Wilmington
      • Wilmington、North Carolina、美国、28411
        • Wilmington Health, PLLC
    • Ohio
      • Cleveland、Ohio、美国、44106
        • University Hospitals Cleveland Medical Center
      • Columbus、Ohio、美国、43215
        • Remington-Davis, Inc
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • Medical University of South Carolina
    • Texas
      • Dallas、Texas、美国、75231
        • Modern Research Associates, PLLC
      • Houston、Texas、美国、77056
        • Austin Institute for Clinical Research
      • Houston、Texas、美国、77008
        • Alpesh D. Desai, DO PLLC
      • London、英国、SE1 9RT
        • Guy's & St Thomas' NHS Foundation Trust
      • Córdoba、西班牙、14001
        • AUDIKA
    • Andalusia
      • Córdoba、Andalusia、西班牙、14004
        • Hospital Universitario Reina Sofia
    • Catalunya [cataluña]
      • Barcelona、Catalunya [cataluña]、西班牙、08036
        • Hospital Clínic de Barcelona
    • LAS Palmas
      • Las Palmas de Gran Canaria、LAS Palmas、西班牙、35010
        • Hospital Universitario de Gran Canaria Doctor Negrín
    • Madrid, Comunidad de
      • Madrid、Madrid, Comunidad de、西班牙、28034
        • Hospital Universitario Ramón y Cajal
    • Kyǒnggi-do
      • Suwon、Kyǒnggi-do、韩国、16247
        • The Catholic University Of Korea St. Vincent's Hospital
      • Suwon、Kyǒnggi-do、韩国、16499
        • Ajou University Hospital
    • Seoul-teukbyeolsi [seoul]
      • Seoul、Seoul-teukbyeolsi [seoul]、韩国、03722
        • Severance Hospital, Yonsei University Health System

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

12年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Participants ≥18 years of age at Screening in Study B7981040. Adolescents (12 to <18 years of age at Screening in the parent study) are also eligible for this study if approved by the local IRB/EC and regulatory health authority.
  • Participants who met the eligibility criteria and completed 52 weeks of study intervention for stable or active nonsegmental vitiligo in Study B7981040
  • The BL visit/first dose in Study B7981041 must be within 30 days after the week 52 visit in Study B7981040

Exclusion Criteria:

  • Participant met the parent study (Study 7981040) discontinuation criteria or discontinued the parent study for any safety-related event
  • Any active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm 1

Participants who previously received 1 ritlecitinib 50 mg capsule QD orally from BL to Week 52 in Study B7981040.

Ritlecitinib 50 mg or Ritlecitinib 100 mg or Placebo will be assigned.

Ritlecitinib 50 mg capsule once daily

Ritlecitinib 100 mg capsule once daily

Matching capsule once daily

实验性的:Arm 2

Participants who previously received 1 placebo 50 mg capsule QD orally from BL to Week 52 in Study B7981040 Ritlecitinib 50 mg or Ritlecitinib 100 mg or Placebo will be assigned

Ritlecitinib 50 mg capsule once daily

Ritlecitinib 100 mg capsule once daily

Matching capsule once daily

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to discontinuation
大体时间:Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)

To evaluate the long-term safety and tolerability of ritlecitinib in adult and adolescent participants with non-segmental vitiligo

Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)
Incidence of clinically significant laboratory abnormalities
大体时间:Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)

To evaluate the long-term safety and tolerability of ritlecitinib in adult and adolescent participants with non-segmental vitiligo

Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)

次要结果测量

结果测量
措施说明
大体时间
Response based on T-VASI75 at weeks 4, 8, 12, 24, 36 and 52
大体时间:Baseline to week 52

Proportion of participants achieving at least a 75% improvement in T-VASI from Baseline

Baseline to week 52
Response based on F-VASI75 at weeks 4, 8, 12, 24, 36 and 52
大体时间:Baseline to week 52

Proportion of participants achieving at least a 75% improvement in F-VASI from Baseline

Baseline to week 52
Response based on T-VASI50 at weeks 4, 8, 12, 24, 36 and 52
大体时间:Baseline to Week 52

Proportion of participants achieving at least a 50% improvement in T-VASI from Baseline

Baseline to Week 52
Response based on F-VASI50 at weeks 4, 8, 12, 24, 36 and 52
大体时间:Baseline to week 52

Proportion of participants achieving at least a 50% improvement in F-VASI from Baseline

Baseline to week 52
Response based on T-VASI90 at weeks 4, 8, 12, 24, 36 and 52
大体时间:Baseline to week 52

Proportion of participants achieving at least a 90% improvement in T-VASI from Baseline

Baseline to week 52
Response based on F-VASI90 at weeks 4, 8, 12, 24, 36 and 52
大体时间:Baseline to week 52

Proportion of participants achieving at least a 90% improvement in F-VASI from Baseline

Baseline to week 52
Response based on T-VASI100 at weeks 4, 8, 12, 24, 36 and 52
大体时间:Baseline to week 52

Proportion of participants achieving at least a 100% improvement in T-VASI from Baseline

Baseline to week 52
Response based on F-VASI100 at weeks 4, 8, 12, 24, 36 and 52
大体时间:Baseline to week 52

Proportion of participants achieving at least a 100% improvement in F-VASI from Baseline

Baseline to week 52
Patient Global Impression of Severity-Face (PGIS-F) at weeks 24, 36, and 52
大体时间:Baseline to week 52

To assess the effect of ritlecitinib compared to placebo on the PGIC-F at weeks 24, 36, and 52

Baseline to week 52
Patient Global Impression of Severity-Overall Vitiligo (PGIS-V) at weeks 24, 36, and 52
大体时间:Baseline to week 52

To assess the effect of ritlecitinib compared to placebo on the PGIC-V at Week 24, 36, and 52

Baseline to week 52
Patient Global Impression of Change-Face (PGIC-F) at week 24, 36, and 52
大体时间:Baseline to week 52

To assess the effect of ritlecitinib compared to placebo on the PGIC-F at Week 24, 36, and 52

Baseline to week 52
Patient Global Impression of Change- Overall vitiligo (PGIC-V) at weeks 24, 36, and 52
大体时间:Baseline to week 52

To assess the effect of ritlecitinib compared to placebo on the PGIC-V at weeks 24, 36, and 52

Baseline to week 52
Proportion of participants achieving disease stabilization
大体时间:Baseline to week 52

The difference in the proportion of participants with stable disease at all scheduled timepoints

Baseline to week 52
Percentage change from baseline (%CFB) in F-VASI at weeks 4, 8, 12, 24, 36, and 52
大体时间:Baseline to week 52

To compare the efficacy of ritlecitinib 100mg QD, 50mg QD, and placebo

Baseline to week 52
Percentage change from baseline (%CFB) in T-VASI at weeks 4, 8, 12, 24, 36, and 52
大体时间:Baseline to week 52

To compare the efficacy of ritlecitinib 100mg QD, 50mg QD, and placebo

Baseline to week 52
Time to loss of response (<F-VASI75 and <T-VASI50 at the same visit).
大体时间:Baseline to week 52

To compare the efficacy of ritlecitinib 100 mg QD, 50 mg QD, and placebo

Baseline to week 52

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Pfizer CT.gov Call Center、Pfizer

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年1月19日

初级完成 (估计的)

2027年3月31日

研究完成 (估计的)

2027年3月31日

研究注册日期

首次提交

2023年11月30日

首先提交符合 QC 标准的

2023年11月30日

首次发布 (实际的)

2023年12月8日

研究记录更新

最后更新发布 (实际的)

2026年9月28日

上次提交的符合 QC 标准的更新

2026年9月24日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • B7981041
  • 2023-505804-42-00 (注册表标识符:CTIS (EU))
  • 2023 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅